NetworkNewsBreaks Archive - Page 2079 of 2139

MondayMar 06, 2017 11:37 am

NetworkNewsBreaks – DryShips, Inc. (NASDAQ: DRYS) Exercises Second Option to Purchase Very Large Gas Carrier for $83.5M

DryShips (NASDAQ: DRYS) said it has exercised its second option under a previously announced option agreement with Hyundai Heavy Industries Co., Ltd. (HHI) to acquire up to four Very Large Gas Carriers (VLGCs) for $83.5 million. Approximately 25% of the purchase price will be paid on closing, expected within March 2017. The remaining balance will be paid in installments until the vessel's delivery, which is currently under construction at HHI. The VLGC will be employed on a fixed rate time charter with five years firm duration to an oil major, and the charterer has options to extend the firm employment…

MondayMar 06, 2017 11:34 am

NetworkNewsBreaks – Micronet Enertec (NASDAQ: MICT) Secures $460,000 Aerospace & Defense Contract

Micronet Enertec Technologies (NASDAQ: MICT) shares are higher after the company said its wholly owned subsidiary, Enertec Systems 2001 Ltd., was recently awarded a purchase order from a global Aerospace & Defense contractor totaling more than $460,000. The contract is a continuous order for the development of a diagnosis and simulation system for a specific missile system, including computer based command and control defense systems. The global Aerospace & Defense contractor is a current customer of Enertec. "We are pleased that a current customer is placing additional orders for our sophisticated fit for purpose products, and especially proud of our…

MondayMar 06, 2017 10:06 am

NetworkNewsBreaks – Galectin Therapeutics (NASDAQ: GALT) Shares Hike on Positive Data from Phase 2a Clinical Trial of GR-MD-02

Shares of Galectin Therapeutics (NASDAQ: GALT) are up more than 8% this morning on the company’s report of positive results from an exploratory, phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis. The research, which was done in partnership with San Antonio Military Medical Center, shows that GR-MD-02 achieved an average PASI (Psoriasis Area and Severity Index) reduction of over 50% in all patients that participated in the 24-week trial. The data also showed no serious adverse events, further demonstrating the safety and efficacy of this novel investigational drug in this patient population. The company will be…

MondayMar 06, 2017 9:13 am

NetworkNewsBreaks – MyDx (MYDX) Makes Debut on HBO’s DAILY VICE News

Shares of MyDx (OTCQB: MYDX) closed Friday’s trade 23% higher after the company said its technology was featured on HBO's DAILY VICE News. MyDx is the developer of MyDx®, the first multi-use handheld chemical analyzer for consumers. The company has been concentrating on the development and market deployment of MyDx sensor technologies and accompanying applications as well as the expansion of its global sales footprint for the product line. The company is also working on creating a comprehensive database of physiologically relevant data from medical cannabis users. MyDx CEO Daniel Yazbeck will also be speaking at the 3rd Annual Cannabis…

FridayMar 03, 2017 3:45 pm

NetworkNewsBreaks – Revance Therapeutics, Inc.’s (NASDAQ: RVNC) ‘Buy’ Rating Reiterated at Aegis Capital

Aegis Capital has reiterated its ‘Buy’ rating and price target of $28 on shares of Revance Therapeutics (NASDAQ: RVNC) following release of the company's fourth quarter and full year results. Revance Therapeutics reported that it had cash and investments of $185.5 million as of December 31, 2016. The company also said the fourth quarter was highly productive for its lead drug candidate, RT002, with the release of data from its phase 2 study for RT002 and the start of patient enrollment for two additional clinical programs evaluating the drug. Additionally, the company will be presenting clinical data from the BELMONT…

FridayMar 03, 2017 3:43 pm

NetworkNewsBreaks – ViewRay, Inc. (NASDAQ: VRAY) Receives FDA Clearance for MRIdian Linac System; ‘Buy’ Rating Reiterated at Aegis Capital

Aegis Capital has reiterated its 'Buy' rating and $11 price target on shares of ViewRay, Inc. (NASDAQ: VRAY). In its recent fourth quarter and full year 2016 financial report, ViewRay reported record revenue of $22.2 million for the year, as well as $133.2 million in backlog. Additionally, the company said it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the MRIdian Linac system, the company's next generation linear accelerator-based MRI-guided radiation therapy system. The first two MRIdian Linac systems in the United States are expected to be installed at Henry Ford Hospital in Detroit and…

FridayMar 03, 2017 12:32 pm

NetworkNewsBreaks – Singlepoint, Inc. (SING) CEO Discusses M&A Strategy in Interview on MoneyTV

Full-service mobile technology and marketing provider Singlepoint, Inc. (OTC: SING) is as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” To view the show, visit www.MoneyTV.net. In this week’s episode, Singlepoint CEO Greg Lambrecht discusses the company’s recent activity, particularly as it relates to its expanded M&A strategy. “We’re really looking for companies in the cannabis business that do not touch the plant, for example a dispensary or grower like Convectium, who we have an LOI with,” Lambrecht noted in the interview.…

FridayMar 03, 2017 11:51 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 3, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: BIOS 18.84% – News: Posts Q4, FY 2016 results CXRX 4.86% – News: Releases comment on CMA statement of objections TRTC 3.60% – News: CEO participating on two upcoming cannabis industry panels FENX 3.01% – News: Law firm posts reminder of March 13 plaintiff deadline NMUS 2.94% – News: Advances NB1222 to human dosage formulation with Catalent APDN 1.28% – News: Releases results from survey on labeling of Aloe vera RAVE 0.92% – News:…

FridayMar 03, 2017 11:21 am

NetworkNewsBreaks – NEMUS Bioscience, Inc. (NMUS), Catalent to Advance Development of NB1222 Human Dosage Formulation

NEMUS Bioscience (OTCQB: NMUS) this morning said it is moving forward with Catalent Pharma Solutions to advance development of a human-dosage suppository formulation of NB1222. NB1222 is the proprietary prodrug of tetrahydrocannabinol (THC) being developed for the treatment and management of chemotherapy-induced nausea and vomiting (CINV). NB1222, also known as the prodrug THC-valine-hemisuccinate, is synthetically manufactured and is not plant-derived. "The global CINV market is a multi-billion dollar opportunity with projected growth as populations live longer, increasing the likelihood of developing a malignancy over time," Nemus CEO and chief medical officer Brian Murphy, M.D. stated in the news release. To…

FridayMar 03, 2017 11:18 am

NetworkNewsBreaks – Achaogen, Inc. (NASDAQ: AKAO) Provides Updates on Drug Candidates During R&D Day

Achaogen (NASDAQ: AKAO) recently held a research and development (R&D) day to provide an overview of its programs. The meeting included presentations from members of Achaogen’s leadership team and medical community key opinion leaders. During the day, the company discussed C-Scape, its new orally administered antibacterial candidate to treat patients with complicated urinary tract infections. Achaogen plans to begin a clinical trial of C-Scape in 2017. Additionally, the R&D day provided an overview of the plazomicin program, including a review of the positive phase 3 results, progress toward the planned New Drug Application (NDA) submission and preparation for commercialization. The…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks